Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Opatija – page 6

93 clinical trials in Opatija, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Opatija at a glance
93
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

93 trials in Opatija

Open in trial search

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:CroatiaCroatia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

IgA nephropathy

Not recruiting

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of SAR441566 compared to placebo for adults with moderate to severe Crohn's disease

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Opatija

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Research focusing on primary prevention of atherosclerotic cardiovascular disease, evaluating innovative treatments to reduce major adverse cardiovascular events.

  • Cardiovascular Death Prevention
  • Heart Attack Risk Reduction
  • Stroke Prevention Strategies

Clinical studies are examining new therapeutic approaches for patients at high risk of cardiovascular complications.

02 Cardiomyopathy Research

Investigations into treatment options for patients with hypertrophic cardiomyopathy, including both obstructive and non-obstructive variants.

  • Symptom Management
  • Functional Improvement
  • Treatment Safety Assessment

Studies are evaluating novel therapies to improve quality of life for patients with cardiac muscle disorders.

03 Vascular Disease Management

Advanced research into atherosclerotic cardiovascular disease treatments, focusing on preventing serious cardiovascular events in high-risk populations.

  • Lipid Management
  • Urgent Coronary Care
  • Long-term Prevention

Therapeutic trials are exploring innovative approaches to manage established vascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.